Huchembio

- Huchembio(CEO): HuChemBio has been founded to develop the first-in-class drugs essential for numerous patients who are suffering from diseases. The existing first-in-class drug development involve numbers of problems including a huge investment, high development failure rate, and long development period. HuchemBio uses its SHADD system to gradually solve the problems of first-class new drug development in a short period of time and continuously discovers first-class new drug candidates to become a leading global new drug development company. - Selective and differentiated drug development(stat3 inhibitor:Highly selective about stat familiy, High activity and low cytotoxicity. Develop treatments for inflammation and autoimmune diseases due to low cytotoxicity. - Huchembio Business model: New drug development(License Out, Collaborative Research, Investment), CRO(Drug Design/Synthetic Design and Synthesis/Collaborative Research), Sales of chiral reagents and APIs.